{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-217439","form_type":"8-K","ticker":"FULC","cik":"0001680581","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2023-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.839874+00:00","generated_at":"2026-06-11T05:38:34.687816+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fulcrum Therapeutics announces FDA lifts clinical hold on FTX-6058 IND for sickle cell disease","bullets":["FDA lifted clinical hold on Fulcrum's IND for FTX-6058 on August 22, 2023.","FTX-6058 is a potential treatment for sickle cell disease.","Fulcrum posted a presentation with amended protocol and planned Phase 1b trial details.","Clinical development can now resume; no financial terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-217439","json":"https://secwatch.observer/filing/0001193125-23-217439.json","markdown":"https://secwatch.observer/filing/0001193125-23-217439.md","text":"https://secwatch.observer/filing/0001193125-23-217439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523217439/0001193125-23-217439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312523217439/d544132d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:38:34.687816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}